A GLP-1-focused peptide API platform: four Type II DMFs on file with the U.S. FDA, 20+ peptide APIs across four product lines, manufactured under cGMP by an FDA-inspected facility with Green List status.
Type II DMFs on file with the U.S. FDA — semaglutide, liraglutide, tirzepatide, retatrutide.
U.S. FDA on-site inspection completed; Green List status; NDC labeler codes 83589 & 83821.
GLP-1 analogues, growth-hormone secretagogues, research peptides and biomedicinal enzymes.
Certificate of Analysis issued for every batch, with full export documentation support.
One platform, full coverage: from regulatory-ready GLP-1 APIs to research peptides and biomedicinal enzymes.
Semaglutide, liraglutide, tirzepatide, retatrutide (all with FDA DMF), plus cagrilintide and eloralintide.
Sermorelin, tesamorelin, ipamorelin, CJC-1295 and CJC-1295 with DAC.
BPC-157, AOD-9604, IGF-1 LR3, MOTS-C, bremelanotide (PT-141), thymosin α1 and β4.
Recombinant carboxypeptidase B and recombinant KexII protease for biopharmaceutical manufacturing.
We align supply to each market's patent and regulatory status, so your sourcing is compliant from day one.
Semaglutide compound patent expired March 2026. ANVISA has approved first generic pens — local manufacturers are scaling production.
Generic-entry window opens in April 2027. We are building partnerships with licensed manufacturers now.
Compound patent in force until December 2031. We supply qualified research institutions and partner with ANDA holders preparing for entry.
Tell us your market and target molecules — we will respond with specifications and COA samples.
Contact Our Export Team